Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, has received US Food and Drug Administration (FDA) approval for Paclitaxle injection USP, 6mg/ml packaged in 30mg/ml, 100mg/ml and 300mg/ml multiple dose vials.
Paclitaxle injection is among the products in the drug shortage list of the America Society of Health-System Pharmacists and the USFDA. The US market of Paclitaxle is about $46 million. The company will launch the product immediately.
The company has also got tentative approval for Oxaliplatin injection which has a US market of about $1.4 billion.
Recently, Onco Therapies received European Union (EU) approval for Oxaliplantin Injection 5mg/ml (10ml, 20ml and 40ml). This is the second European approval out of the 22 filings made by OTL in the year 2010 for products which have a combined market value of over $5 billion.
Strides Arcolab is global pharmaceuticals company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with emphasis on sterlite injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: